You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVardenafil
Accession NumberDB00862  (APRD00699)
TypeSmall Molecule
GroupsApproved
DescriptionVardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
Structure
Thumb
Synonyms
2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one
Levitra
Vardenafil
Vardénafil
Vardenafil
Vardenafilum
External Identifiers
  • BAY 389456
  • DE 19750085 1997
  • WO 99/24433 1999
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LevitraTablet, film coated5 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated20 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated20 mg/1OralKAISER FOUNDATION HOSPITALS2011-10-28Not applicableUs
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-05-15Not applicableUs
LevitraTablet, film coated10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mg/1OralGlaxo Smith Kline Llc2003-08-25Not applicableUs
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-04-22Not applicableUs
LevitraTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2011-04-22Not applicableUs
LevitraTablet, film coated5 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated5 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-05-15Not applicableUs
LevitraTablet, film coated20 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated5 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet5 mgOralBayer Inc2004-03-17Not applicableCanada
LevitraTablet, film coated20 mg/1OralGlaxo Smith Kline Llc2003-08-25Not applicableUs
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2004-01-27Not applicableUs
LevitraTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2008-05-15Not applicableUs
LevitraTablet, film coated5 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-04-22Not applicableUs
LevitraTablet, film coated2.5 mg/1OralGlaxo Smith Kline Llc2003-08-25Not applicableUs
LevitraTablet, film coated20 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet10 mgOralBayer Inc2004-03-17Not applicableCanada
LevitraTablet, film coated20 mg/1Oralbryant ranch prepack2008-05-15Not applicableUs
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2004-03-05Not applicableUs
LevitraTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-05-15Not applicableUs
LevitraTablet, film coated5 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated5 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-04-22Not applicableUs
LevitraTablet, film coated5 mg/1OralGlaxo Smith Kline Llc2003-04-23Not applicableUs
LevitraTablet, film coated20 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated10 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet, film coated20 mgOralBayer Pharma Ag  2003-03-06Not applicableEu
LevitraTablet20 mgOralBayer Inc2004-03-17Not applicableCanada
StaxynTablet, orally disintegrating10 mg/1OralPhysicians Total Care, Inc.2012-03-08Not applicableUs
StaxynTablet, orally disintegrating10 mgOralBayer Inc2011-08-25Not applicableCanada
StaxynTablet, orally disintegrating11.85 mg/1OralGlaxo Smith Kline Llc2011-04-21Not applicableUs
VivanzaTablet, film coated10 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated5 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, orally disintegrating10 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated20 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated10 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated20 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated5 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated5 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated10 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated20 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated5 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated10 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated10 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated20 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated5 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
VivanzaTablet, film coated20 mgOralBayer Pharma Ag  2003-03-04Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VivanzaGlaxoSmithKline
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vardenafil hydrochloride
ThumbNot applicableDBSALT000933
Vardenafil hydrochloride trihydrate
330808-88-3
Thumb
  • InChI Key: FBCDRHDULQYRTB-UHFFFAOYSA-N
  • Monoisotopic Mass: 578.2289465
  • Average Mass: 579.11
DBSALT001741
Categories
UNIIUCE6F4125H
CAS number224785-90-4
WeightAverage: 488.603
Monoisotopic: 488.220574232
Chemical FormulaC23H32N6O4S
InChI KeySECKRCOLJRRGGV-UHFFFAOYSA-N
InChI
InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
IUPAC Name
2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin-4-one
SMILES
CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1
Pharmacology
IndicationUsed for the treatment of erectile dysfunction
Structured Indications
PharmacodynamicsVardenafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Vardenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with vardenafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, vardenafil should not cause an erection.
Mechanism of actionVardenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by vardenafil enhances erectile function by increasing the amount of cGMP.
TargetKindPharmacological actionActionsOrganismUniProt ID
cGMP-specific 3',5'-cyclic phosphodiesteraseProteinyes
inhibitor
HumanO76074 details
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaProteinunknown
allosteric modulator
HumanP18545 details
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaProteinunknown
allosteric modulator
HumanQ13956 details
Related Articles
AbsorptionVardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.
Volume of distribution
  • 208 L
Protein binding95%
Metabolism

Vardenafil is metabolized predominantly by the hepatic enzyme CYP3A4, with contribution from the CYP3A5 and CYP2C isoforms. The major circulating metabolite, M1, results from desethylation at the piperazine moiety of vardenafil. M1 shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 28% of that of vardenafil.

Route of eliminationAfter oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).
Half life4-5 hours
Clearance
  • 56 L/h
ToxicitySymptoms of overdose include vision changes and back and muscle pain.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololVardenafil may increase the antihypertensive activities of Acebutolol.Approved
AlfuzosinVardenafil may increase the hypotensive activities of Alfuzosin.Approved, Investigational
AliskirenVardenafil may increase the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololVardenafil may increase the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Vardenafil is combined with Alprostadil.Approved, Investigational
AmbrisentanVardenafil may increase the antihypertensive activities of Ambrisentan.Approved, Investigational
AmiodaroneThe serum concentration of Vardenafil can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineVardenafil may increase the antihypertensive activities of Amlodipine.Approved
Amyl NitriteVardenafil may increase the vasodilatory activities of Amyl Nitrite.Approved
AnagrelideVardenafil may increase the QTc-prolonging activities of Anagrelide.Approved
AprepitantThe serum concentration of Vardenafil can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideVardenafil may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherVardenafil may increase the QTc-prolonging activities of Artemether.Approved
AsenapineVardenafil may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Vardenafil can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololVardenafil may increase the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Vardenafil can be decreased when combined with Atomoxetine.Approved
AzithromycinVardenafil may increase the QTc-prolonging activities of Azithromycin.Approved
BedaquilineVardenafil may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilVardenafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
BendroflumethiazideVardenafil may increase the antihypertensive activities of Bendroflumethiazide.Approved
BepridilVardenafil may increase the antihypertensive activities of Bepridil.Approved, Withdrawn
BetaxololVardenafil may increase the antihypertensive activities of Betaxolol.Approved
BethanidineVardenafil may increase the antihypertensive activities of Bethanidine.Approved
BexaroteneThe serum concentration of Vardenafil can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostVardenafil may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
BisoprololVardenafil may increase the antihypertensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Vardenafil can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Vardenafil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vardenafil can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumVardenafil may increase the antihypertensive activities of Bretylium.Approved
BrimonidineVardenafil may increase the antihypertensive activities of Brimonidine.Approved
BucindololVardenafil may increase the hypotensive activities of Bucindolol.Investigational
BupranololVardenafil may increase the antihypertensive activities of Bupranolol.Approved
CandesartanVardenafil may increase the antihypertensive activities of Candesartan.Approved
CandoxatrilVardenafil may increase the antihypertensive activities of Candoxatril.Experimental
CaptoprilVardenafil may increase the antihypertensive activities of Captopril.Approved
CarbamazepineThe metabolism of Vardenafil can be increased when combined with Carbamazepine.Approved, Investigational
CarteololVardenafil may increase the antihypertensive activities of Carteolol.Approved
CarvedilolVardenafil may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololVardenafil may increase the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Vardenafil can be increased when it is combined with Ceritinib.Approved
ChloroquineVardenafil may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideVardenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineVardenafil may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneVardenafil may increase the antihypertensive activities of Chlorthalidone.Approved
CilazaprilVardenafil may increase the antihypertensive activities of Cilazapril.Approved
CiprofloxacinVardenafil may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideVardenafil may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramVardenafil may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe serum concentration of Vardenafil can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Vardenafil can be decreased when combined with Clemastine.Approved
ClonidineVardenafil may increase the antihypertensive activities of Clonidine.Approved
ClotrimazoleThe metabolism of Vardenafil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineVardenafil may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Vardenafil can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Vardenafil can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibVardenafil may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineVardenafil may increase the antihypertensive activities of Cryptenamine.Approved
CyclosporineThe metabolism of Vardenafil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideVardenafil may increase the antihypertensive activities of Cyclothiazide.Approved
DabrafenibThe serum concentration of Vardenafil can be decreased when it is combined with Dabrafenib.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Vardenafil.Investigational
DarunavirThe serum concentration of Vardenafil can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Vardenafil can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinVardenafil may increase the antihypertensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Vardenafil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Vardenafil can be decreased when combined with Delavirdine.Approved
DeserpidineVardenafil may increase the antihypertensive activities of Deserpidine.Approved
DexamethasoneThe serum concentration of Vardenafil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideVardenafil may increase the antihypertensive activities of Diazoxide.Approved
DihydralazineVardenafil may increase the antihypertensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Vardenafil can be decreased when combined with Dihydroergotamine.Approved
DiltiazemVardenafil may increase the antihypertensive activities of Diltiazem.Approved
DisopyramideVardenafil may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideVardenafil may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronVardenafil may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneVardenafil may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideVardenafil may increase the antihypertensive activities of Dorzolamide.Approved
DoxazosinVardenafil may increase the hypotensive activities of Doxazosin.Approved
DoxycyclineThe metabolism of Vardenafil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneVardenafil may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolVardenafil may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
EfavirenzThe serum concentration of Vardenafil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineVardenafil may increase the antihypertensive activities of Efonidipine.Approved
EliglustatVardenafil may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilVardenafil may increase the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatVardenafil may increase the antihypertensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Vardenafil can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolVardenafil may increase the antihypertensive activities of Epoprostenol.Approved
EprosartanVardenafil may increase the antihypertensive activities of Eprosartan.Approved
Erythrityl TetranitrateVardenafil may increase the vasodilatory activities of Erythrityl Tetranitrate.Approved
ErythromycinThe serum concentration of Vardenafil can be increased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinVardenafil may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramVardenafil may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Vardenafil can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthanolEthanol may increase the hypotensive activities of Vardenafil.Approved
EtravirineThe serum concentration of Vardenafil can be decreased when it is combined with Etravirine.Approved
FelodipineVardenafil may increase the antihypertensive activities of Felodipine.Approved, Investigational
FenoldopamVardenafil may increase the antihypertensive activities of Fenoldopam.Approved
FlecainideVardenafil may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleThe serum concentration of Vardenafil can be increased when it is combined with Fluconazole.Approved
FluoxetineVardenafil may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolVardenafil may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineThe metabolism of Vardenafil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vardenafil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vardenafil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilVardenafil may increase the antihypertensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Vardenafil can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Vardenafil can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidVardenafil may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinVardenafil may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinVardenafil may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronVardenafil may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzVardenafil may increase the antihypertensive activities of Guanabenz.Approved
GuanadrelVardenafil may increase the antihypertensive activities of Guanadrel.Approved
GuanethidineVardenafil may increase the antihypertensive activities of Guanethidine.Approved
GuanfacineVardenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
HaloperidolVardenafil may increase the QTc-prolonging activities of Haloperidol.Approved
HexamethoniumVardenafil may increase the antihypertensive activities of Hexamethonium.Experimental
HydralazineVardenafil may increase the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideVardenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideVardenafil may increase the antihypertensive activities of Hydroflumethiazide.Approved
IbutilideVardenafil may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Vardenafil can be increased when it is combined with Idelalisib.Approved
IloperidoneVardenafil may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Vardenafil can be decreased when combined with Imatinib.Approved
ImidaprilVardenafil may increase the antihypertensive activities of Imidapril.Investigational
IndapamideVardenafil may increase the antihypertensive activities of Indapamide.Approved
IndenololVardenafil may increase the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Vardenafil can be increased when it is combined with Indinavir.Approved
IndoraminVardenafil may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanVardenafil may increase the antihypertensive activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Vardenafil can be decreased when combined with Isavuconazonium.Approved, Investigational
Isosorbide DinitrateVardenafil may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateVardenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
IsradipineVardenafil may increase the antihypertensive activities of Isradipine.Approved
ItraconazoleThe serum concentration of Vardenafil can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Vardenafil can be increased when it is combined with Ivacaftor.Approved
KetanserinVardenafil may increase the antihypertensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Vardenafil can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolVardenafil may increase the hypotensive activities of Labetalol.Approved
LacidipineVardenafil may increase the antihypertensive activities of Lacidipine.Approved
LatanoprostVardenafil may increase the antihypertensive activities of Latanoprost.Approved, Investigational
LenvatinibVardenafil may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineVardenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
LeuprolideVardenafil may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinVardenafil may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LisinoprilVardenafil may increase the antihypertensive activities of Lisinopril.Approved, Investigational
LofexidineVardenafil may increase the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Vardenafil can be increased when it is combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Vardenafil.Approved
LosartanVardenafil may increase the antihypertensive activities of Losartan.Approved
LovastatinThe metabolism of Vardenafil can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Vardenafil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Vardenafil can be increased when combined with Lumacaftor.Approved
LumefantrineVardenafil may increase the QTc-prolonging activities of Lumefantrine.Approved
MacitentanVardenafil may increase the antihypertensive activities of Macitentan.Approved
ManidipineVardenafil may increase the antihypertensive activities of Manidipine.Approved
MecamylamineVardenafil may increase the antihypertensive activities of Mecamylamine.Approved
MethadoneVardenafil may increase the QTc-prolonging activities of Methadone.Approved
MethyldopaVardenafil may increase the antihypertensive activities of Methyldopa.Approved
MetipranololVardenafil may increase the antihypertensive activities of Metipranolol.Approved
MetolazoneVardenafil may increase the antihypertensive activities of Metolazone.Approved
MetoprololVardenafil may increase the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineVardenafil may increase the antihypertensive activities of Metyrosine.Approved
MibefradilVardenafil may increase the antihypertensive activities of Mibefradil.Withdrawn
MifepristoneMifepristone may increase the QTc-prolonging activities of Vardenafil.Approved, Investigational
MinoxidilVardenafil may increase the antihypertensive activities of Minoxidil.Approved
MitotaneThe serum concentration of Vardenafil can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Vardenafil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilVardenafil may increase the antihypertensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Vardenafil.Approved
MoxifloxacinVardenafil may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineVardenafil may increase the antihypertensive activities of Moxonidine.Approved
NadololVardenafil may increase the antihypertensive activities of Nadolol.Approved
NafcillinThe serum concentration of Vardenafil can be decreased when it is combined with Nafcillin.Approved
NaftopidilVardenafil may increase the antihypertensive activities of Naftopidil.Investigational
NebivololVardenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Vardenafil can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Vardenafil can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Vardenafil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Vardenafil can be increased when combined with Nevirapine.Approved
NicardipineVardenafil may increase the antihypertensive activities of Nicardipine.Approved
NicorandilVardenafil may increase the antihypertensive activities of Nicorandil.Approved
NiguldipineVardenafil may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibVardenafil may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineVardenafil may increase the antihypertensive activities of Nilvadipine.Approved
NimodipineVardenafil may increase the antihypertensive activities of Nimodipine.Approved
NisoldipineVardenafil may increase the antihypertensive activities of Nisoldipine.Approved
NitrendipineVardenafil may increase the antihypertensive activities of Nitrendipine.Approved
NitroglycerinVardenafil may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
NitroprussideVardenafil may increase the antihypertensive activities of Nitroprusside.Approved
OfloxacinVardenafil may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Vardenafil can be decreased when combined with Olaparib.Approved
OlmesartanVardenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
OmapatrilatVardenafil may increase the antihypertensive activities of Omapatrilat.Investigational
OndansetronVardenafil may increase the QTc-prolonging activities of Ondansetron.Approved
OsimertinibThe serum concentration of Vardenafil can be increased when it is combined with Osimertinib.Approved
OxprenololVardenafil may increase the antihypertensive activities of Oxprenolol.Approved
PalbociclibThe serum concentration of Vardenafil can be increased when it is combined with Palbociclib.Approved
PaliperidoneVardenafil may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatVardenafil may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PargylineVardenafil may increase the antihypertensive activities of Pargyline.Approved
PazopanibVardenafil may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololVardenafil may increase the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineVardenafil may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Vardenafil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumVardenafil may increase the antihypertensive activities of Pentolinium.Approved
PerflutrenVardenafil may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilVardenafil may increase the antihypertensive activities of Perindopril.Approved
PhenobarbitalThe metabolism of Vardenafil can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineVardenafil may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhentolamineVardenafil may increase the antihypertensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Vardenafil can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideVardenafil may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilVardenafil may increase the antihypertensive activities of Pinacidil.Withdrawn
PindololVardenafil may increase the antihypertensive activities of Pindolol.Approved
PolythiazideVardenafil may increase the antihypertensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Vardenafil can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrazosinVardenafil may increase the hypotensive activities of Prazosin.Approved
PrimaquineVardenafil may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Vardenafil can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideVardenafil may increase the QTc-prolonging activities of Procainamide.Approved
PromazineVardenafil may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneVardenafil may increase the QTc-prolonging activities of Propafenone.Approved
PropranololVardenafil may increase the antihypertensive activities of Propranolol.Approved, Investigational
QuetiapineVardenafil may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilVardenafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
QuinidineVardenafil may increase the QTc-prolonging activities of Quinidine.Approved
QuinineVardenafil may increase the QTc-prolonging activities of Quinine.Approved
RamiprilVardenafil may increase the antihypertensive activities of Ramipril.Approved
RanolazineThe metabolism of Vardenafil can be decreased when combined with Ranolazine.Approved, Investigational
RemikirenVardenafil may increase the antihypertensive activities of Remikiren.Approved
RescinnamineVardenafil may increase the antihypertensive activities of Rescinnamine.Approved
ReserpineVardenafil may increase the antihypertensive activities of Reserpine.Approved
RifabutinThe metabolism of Vardenafil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Vardenafil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Vardenafil can be increased when combined with Rifapentine.Approved
RilmenidineVardenafil may increase the antihypertensive activities of Rilmenidine.Investigational
RiociguatVardenafil may increase the hypotensive activities of Riociguat.Approved
RitonavirThe serum concentration of Vardenafil can be increased when it is combined with Ritonavir.Approved, Investigational
SaprisartanVardenafil may increase the antihypertensive activities of Saprisartan.Experimental
SapropterinSapropterin may increase the hypotensive activities of Vardenafil.Approved, Investigational
SaquinavirThe serum concentration of Vardenafil can be increased when it is combined with Saquinavir.Approved, Investigational
SelexipagVardenafil may increase the antihypertensive activities of Selexipag.Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Vardenafil.Approved, Investigational
SilodosinVardenafil may increase the hypotensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Vardenafil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vardenafil can be increased when it is combined with Simeprevir.Approved
SitaxentanVardenafil may increase the antihypertensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolVardenafil may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilVardenafil may increase the antihypertensive activities of Spirapril.Approved
St. John's WortThe serum concentration of Vardenafil can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Vardenafil can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleVardenafil may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
TadalafilThe risk or severity of adverse effects can be increased when Tadalafil is combined with Vardenafil.Approved, Investigational
TamsulosinVardenafil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TelaprevirThe serum concentration of Vardenafil can be increased when it is combined with Telaprevir.Approved
TelavancinVardenafil may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Vardenafil can be increased when it is combined with Telithromycin.Approved
TelmisartanVardenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TemocaprilVardenafil may increase the antihypertensive activities of Temocapril.Experimental, Investigational
TerazosinVardenafil may increase the hypotensive activities of Terazosin.Approved
TerlipressinVardenafil may increase the antihypertensive activities of Terlipressin.Approved, Investigational
TetrabenazineVardenafil may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineVardenafil may increase the QTc-prolonging activities of Thioridazine.Approved
TiboloneVardenafil may increase the antihypertensive activities of Tibolone.Approved
TiclopidineThe metabolism of Vardenafil can be decreased when combined with Ticlopidine.Approved
TicrynafenVardenafil may increase the antihypertensive activities of Ticrynafen.Withdrawn
TimololVardenafil may increase the antihypertensive activities of Timolol.Approved
TocilizumabThe serum concentration of Vardenafil can be decreased when it is combined with Tocilizumab.Approved
TolazolineVardenafil may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TorasemideVardenafil may increase the antihypertensive activities of Torasemide.Approved
ToremifeneVardenafil may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilVardenafil may increase the antihypertensive activities of Trandolapril.Approved
TravoprostVardenafil may increase the antihypertensive activities of Travoprost.Approved
TreprostinilVardenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideVardenafil may increase the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinVardenafil may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanVardenafil may increase the antihypertensive activities of Trimethaphan.Approved
UdenafilThe risk or severity of adverse effects can be increased when Vardenafil is combined with Udenafil.Approved, Investigational
UnoprostoneVardenafil may increase the antihypertensive activities of Unoprostone.Approved
ValsartanVardenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
VandetanibVardenafil may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibVardenafil may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Vardenafil can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Vardenafil can be decreased when combined with Verapamil.Approved
VinpocetineVardenafil may increase the antihypertensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Vardenafil can be increased when it is combined with Voriconazole.Approved, Investigational
XylometazolineVardenafil may increase the antihypertensive activities of Xylometazoline.Approved
ZiprasidoneVardenafil may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolVardenafil may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Yogesh S. Deshpande, Sandra Brueck, Julia Schulze Nahrup, Birgit Schnitter, Ganesh Gat, Javed Hussain, “PROCESS FOR THE PREPARATION OF A MEDICAMENT COMPRISING VARDENAFIL HYDROCHLORIDE TRIHYDRATE.” U.S. Patent US20100159003, issued June 24, 2010.

US20100159003
General ReferencesNot Available
External Links
ATC CodesG04BE09
AHFS Codes
  • 24:12.12
PDB EntriesNot Available
FDA labelDownload (535 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6682
Caco-2 permeable+0.5502
P-glycoprotein substrateSubstrate0.7415
P-glycoprotein inhibitor IInhibitor0.6976
P-glycoprotein inhibitor IIInhibitor0.8552
Renal organic cation transporterNon-inhibitor0.6975
CYP450 2C9 substrateNon-substrate0.6386
CYP450 2D6 substrateSubstrate0.7909
CYP450 3A4 substrateSubstrate0.697
CYP450 1A2 substrateNon-inhibitor0.8215
CYP450 2C9 inhibitorInhibitor0.7426
CYP450 2D6 inhibitorNon-inhibitor0.8464
CYP450 2C19 inhibitorNon-inhibitor0.7472
CYP450 3A4 inhibitorInhibitor0.8857
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7205
Ames testNon AMES toxic0.5748
CarcinogenicityNon-carcinogens0.6141
BiodegradationNot ready biodegradable0.8875
Rat acute toxicity2.6208 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Inhibitor0.7696
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bayer healthcare pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral10 mg
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral20 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral5 mg/1
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral11.85 mg/1
Prices
Unit descriptionCostUnit
Levitra 10 mg tablet19.04USD tablet
Levitra 20 mg tablet19.04USD tablet
Levitra 5 mg tablet19.04USD tablet
Levitra 2.5 mg tablet18.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2309332 No2002-12-032018-10-31Canada
US6362178 No1998-10-312018-10-31Us
US7696206 No1998-10-312018-10-31Us
US8273876 No2007-07-232027-07-23Us
US8613950 No2008-12-232028-12-23Us
US8841446 No2003-07-032023-07-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point192 °CNot Available
water solubility0.11 mg/mL (HCl salt)Not Available
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.325 mg/mLALOGPS
logP2.18ALOGPS
logP1.33ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)8.01ChemAxon
pKa (Strongest Basic)6.21ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area109.13 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity142.71 m3·mol-1ChemAxon
Polarizability53.22 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Phenol ether
  • N-alkylpiperazine
  • Alkyl aryl ether
  • 1,2,4-triazine
  • Triazine
  • Piperazine
  • N-substituted imidazole
  • 1,4-diazinane
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Imidazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH: A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol. 2006 Nov;70(5):1822-31. Epub 2006 Aug 22. [PubMed:16926278 ]
  2. Carrier S: Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol. 2003 Feb;10 Suppl 1:12-6. [PubMed:12625845 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Kim NN, Huang YH, Goldstein I, Bischoff E, Traish AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci. 2001 Sep 28;69(19):2249-56. [PubMed:11669467 ]
  5. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001 Oct;13(5):282-90. [PubMed:11890515 ]
  6. Scheen AJ: [Medication of the month. Vardenafil (Levitra)]. Rev Med Liege. 2003 Sep;58(9):576-9. [PubMed:14626653 ]
  7. Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003 Sep 4;425(6953):98-102. [PubMed:12955149 ]
  8. Wang H, Ye M, Robinson H, Francis SH, Ke H: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008 Jan;73(1):104-10. Epub 2007 Oct 24. [PubMed:17959709 ]
  9. Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3. [PubMed:17979301 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Enzyme inhibitor activity
Specific Function:
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Gene Name:
PDE6G
Uniprot ID:
P18545
Molecular Weight:
9643.09 Da
References
  1. Zhang XJ, Cahill KB, Elfenbein A, Arshavsky VY, Cote RH: Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. J Biol Chem. 2008 Oct 31;283(44):29699-705. doi: 10.1074/jbc.M803948200. Epub 2008 Sep 8. [PubMed:18779324 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Enzyme inhibitor activity
Specific Function:
Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
Gene Name:
PDE6H
Uniprot ID:
Q13956
Molecular Weight:
9074.36 Da
References
  1. Zhang XJ, Cahill KB, Elfenbein A, Arshavsky VY, Cote RH: Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. J Biol Chem. 2008 Oct 31;283(44):29699-705. doi: 10.1074/jbc.M803948200. Epub 2008 Sep 8. [PubMed:18779324 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:48